-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On June 7, local time, the U.
S.
Food and Drug Administration (FDA) issued a statement on its official website stating that it approved the Aduhelm (aducanumab) developed by the pharmaceutical company Biogen to treat patients with Alzheimer’s disease.
It is the first new treatment approved for Alzheimer's disease since 2003
.
According to reports, the company and its Japanese partner Eisai Co.
, Ltd.
stated in an announcement that the annual treatment cost of Adunazumab is $56,000
.
Affected by this news, Biogen's stock price rose 58%
According to the timeline, Biogen completed the submission of aducanumab listing application materials on July 8, 2020, and was officially accepted by the FDA on August 7, 2020, and obtained priority review qualifications.